Skip Navigation

This Article
Right arrow FREE Full Text (PDF) Freely available
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Boswell, F. J.
Right arrow Articles by Wise, R.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Boswell, F. J.
Right arrow Articles by Wise, R.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Journal of Antimicrobial Chemotherapy, Vol 39, 29-32, Copyright © 1997 by The British Society for Antimicrobial Chemotherapy

ORIGINAL ARTICLES

Time-kill kinetics of quinupristin/dalfopristin on Staphylococcus aureus with and without a raised MBC evaluated by two methods

FJ Boswell, J Sunderland, JM Andrews and R Wise
Department of Medical Microbiology, City Hospital NHS Trust, Birmingham, UK.

Some strains of staphylococci have raised MBCs of quinupristin/dalfopristin compared with their MICs. In this study, the time-kill kinetics of quinupristin/dalfopristin at 2 mg/L on two strains of Staphylococcus aureus were determined by viable count and intracellular ATP measurement. After 24 h exposure to quinupristin/dalfopristin, the percentage survival of the strain with a raised MBC was 5.9 and that of the strain with a normal MBC was 0.04. The time-kill kinetics of the strain with a raised MBC were analogous to those associated with phenotypic tolerance.
Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 J Antimicrob ChemotherHome page
D. M. Livermore
Quinupristin/dalfopristin and linezolid: where, when, which and whether to use?
J. Antimicrob. Chemother., September 1, 2000; 46(3): 347 - 350.
[Full Text] [PDF]

Home page
 J Antimicrob ChemotherHome page
I. Odenholt, T. Cars, and E. Lowdin
Pharmacodynamic studies of trovafloxacin and grepafloxacin in vitro against Gram-positive and Gram-negative bacteria
J. Antimicrob. Chemother., July 1, 2000; 46(1): 35 - 43.
[Abstract] [Full Text] [PDF]

Home page
 J Antimicrob ChemotherHome page
S. Gander and R. Finch
The effects of exposure at constant (1 h) or exponentially decreasing concentrations of quinupristin/dalfopristin on biofilms of Gram-positive bacteria
J. Antimicrob. Chemother., July 1, 2000; 46(1): 61 - 67.
[Abstract] [Full Text] [PDF]

Home page
 Antimicrob. Agents Chemother.Home page
J. S. Bradley, G. L. Kearns, M. D. Reed, E. V. Capparelli, J. Vincent, and The Pediatric Pharmacology Research Unit Network
Pharmacokinetics of a Fluoronaphthyridone, Trovafloxacin (CP 99,219), in Infants and Children following Administration of a Single Intravenous Dose of Alatrofloxacin
Antimicrob. Agents Chemother., May 1, 2000; 44(5): 1195 - 1199.
[Abstract] [Full Text]

Home page
 Antimicrob. Agents Chemother.Home page
P.-L. Ho, T.-L. Que, D. N.-C. Tsang, T.-K. Ng, K.-H. Chow, and W.-H. Seto
Emergence of Fluoroquinolone Resistance among Multiply Resistant Strains of Streptococcus pneumoniae in Hong Kong
Antimicrob. Agents Chemother., May 1, 1999; 43(5): 1310 - 1313.
[Abstract] [Full Text]


Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.